Skip Navigation

Cardiovascular Research 2007 76(3):506-516; doi:10.1016/j.cardiores.2007.07.008
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Min, L.-J.
Right arrow Articles by Horiuchi, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Min, L.-J.
Right arrow Articles by Horiuchi, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2007, European Society of Cardiology

Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence

Li-Juan Min, Masaki Mogi, Jun Iwanami, Jian-Mei Li, Akiko Sakata, Teppei Fujita, Kana Tsukuda, Masaru Iwai and Masatsugu Horiuchi*

Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Tohon, Ehime 791-0295, Japan

*Corresponding author. Tel.: +81 89 960 5248; fax: +81 89 960 5251. horiuchi{at}m.ehime-u.ac.jp

Objective Our aim was to examine the possible cross-talk of angiotensin II (Ang II) and aldosterone (Aldo) in the regulation of vascular cell senescence in cultured vascular smooth muscle cells (VSMC).

Methods VSMC were prepared from thoracic aorta of adult male Sprague–Dawley rats. Cellular senescence was evaluated by senescence-associated β-galactosidase (SA-β-gal) staining and expression of p21, p53, p16, and p27. Oxidative stress was determined by measuring NADPH oxidase activity and superoxide production. Signal transduction was examined by immunoblot analysis with or without RNA interference methods.

Results Persistent Ang II (100 nM) stimulation increased SA-β-gal-stained VSMC and enhanced expression of p21, p53, p16, p27 and Ki-ras2A. These effects of Ang II were markedly inhibited by treatment with a selective AT1 receptor blocker, valsartan, but partially attenuated by a mineralocorticoid receptor antagonist, spironolactone. The culture medium of VSMC treated with Ang II (100 nM) showed a time-dependent increase in Aldo concentration, which increased senescent VSMC. Antioxidant, N-acetyl-L-cysteine or superoxide dismutase attenuated Ang II- or Aldo-induced VSMC senescence and Ki-ras2A expression. A lower dose combination of Ang II (100 pM) and Aldo (1 pM) significantly enhanced SA-β-gal-stained VSMC with increases in expression of p21, p53, p16, p27 and Ki-ras2A, oxidative stress, and activity of transcription factors such as NF-{kappa}B, AP-1, whereas Ang II or Aldo alone at these doses did not affect these parameters. Ki-ras2A-siRNA treatment attenuated senescent VSMC, expression of p21, p53, p16 and p27, oxidative stress induced by Ang II or a lower dose combination of Ang II and Aldo.

Conclusion These results suggest that Ang II and Aldo exert cross-talk in VSMC senescence with involvement of oxidative stress and Ki-ras2A, and could provide a therapeutic benefit for age-related vascular disorders by blockade of both Ang II and Aldo.

KEYWORDS Renin–angiotensin system; Aging; Receptor; Signal transduction; Smooth muscle


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Circ. Res.Home page
C. A. Lemarie, S. M.C. Simeone, A. Nikonova, T. Ebrahimian, M.-E. Deschenes, T. M. Coffman, P. Paradis, and E. L. Schiffrin
Aldosterone-Induced Activation of Signaling Pathways Requires Activity of Angiotensin Type 1a Receptors
Circ. Res., October 23, 2009; 105(9): 852 - 859.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
J. R. Sowers, A. Whaley-Connell, and M. Epstein
Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension
Ann Intern Med, June 2, 2009; 150(11): 776 - 783.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Fujita, M. Mogi, L.-J. Min, J. Iwanami, K. Tsukuda, A. Sakata, H. Okayama, M. Iwai, C. Nahmias, J. Higaki, et al.
Attenuation of Cuff-Induced Neointimal Formation by Overexpression of Angiotensin II Type 2 Receptor-Interacting Protein 1
Hypertension, April 1, 2009; 53(4): 688 - 693.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
P. Wang, T.-Y. Xu, Y.-F. Guan, D.-F. Su, G.-R. Fan, and C.-Y. Miao
Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide
Cardiovasc Res, February 1, 2009; 81(2): 370 - 380.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
P. Mulder, V. Mellin, J. Favre, M. Vercauteren, I. Remy-Jouet, C. Monteil, V. Richard, S. Renet, J. P. Henry, A. Y. Jeng, et al.
Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone
Eur. Heart J., September 1, 2008; 29(17): 2171 - 2179.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A.C. Montezano, G.E. Callera, A. Yogi, Y. He, R.C. Tostes, G. He, E.L. Schiffrin, and R.M. Touyz
Aldosterone and Angiotensin II Synergistically Stimulate Migration in Vascular Smooth Muscle Cells Through c-Src-Regulated Redox-Sensitive RhoA Pathways
Arterioscler Thromb Vasc Biol, August 1, 2008; 28(8): 1511 - 1518.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. H. Westhoff, K. F. Hilgers, M. P. Steinbach, A. Hartner, B. Klanke, K. Amann, and A. Melk
Hypertension Induces Somatic Cellular Senescence in Rats and Humans by Induction of Cell Cycle Inhibitor p16INK4a
Hypertension, July 1, 2008; 52(1): 123 - 129.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.